Abstracts tagged "Hematopoietic stem cells"

Abstract Number: 072 • 2020 Pediatric Rheumatology Symposium
Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases
Camille Beaufils¹, Catherine Proulx ², Annaliesse Blincoe ³, Pierre Teira ⁴, Henrique Bittencourt ⁴, Sonia Cellot ⁵, Michel Duval ⁴, Johannes Roth ⁶, Marie-Paule Morin ⁷, Jean Jacques De Bruycker ⁷, Julie Couture ⁷, Kathryn Samaan ⁸, Helene Decaluwe ⁷, Fabien Touzot ⁷, Elie Haddad ⁷ and Julie Barsalou ⁷, ¹Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Quebec, Canada, ²Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada, ³Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Canada, ⁴Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁵Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada, ⁶Division of Pediatric Rheumatology, Children Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada, ⁷Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁸Division of Pediatric Rheumatology-Immunology,-Allergy, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
Background/Purpose: Patients with refractory rheumatic diseases face poor quality of life, long-term sequelae and life-threatening complications. With advances in allogenic hematopoietic stem cell transplantation (allo-HSCT),…
Abstract Number: 2912 • 2019 ACR/ARP Annual Meeting
Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study
Sandra van Bijnen ¹, Maaike Boonstra ², Els van den Ende ³, Lucia Kroft ², Bram Geurts ¹, Miranda Snoeren ¹, Anne Schouffoer ², Julia Spierings ⁴, Jacob van Laar ⁵, Thomas Huizinga ⁶, Alexandre Voskuyl ⁷, Walter van der Velden ¹, Frank van den Hoogen ³, Jeska de Vries-Bouwstra ⁶ and Madelon Vonk⁸, ¹Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³Department of Rheumatology, Radboud University Medical Center, Nijmegen, Gelderland, Netherlands, ⁴Utrecht Medical Centre, Utrecht, Utrecht, Netherlands, ⁵UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Amsterdam Univiversity Medical Centre, Amsterdam, Noord-Holland, Netherlands, ⁸Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands
Background/Purpose: Autologous hematopoietic stemcell transplantation (HSCT) has shown to improve survival of SSc patients with poor prognosis, but is hampered by treatment related mortality (TRM).…
Abstract Number: 34 • 2018 ACR/ARHP Annual Meeting
Microbiome-Drived Aberration of Hematopoietic Stem Cell Development Facilitates Immune Deregulation on the Onset of Collagen-Induced Arthritis in Mice
Peiqing Yang¹, Lingchong Su¹, Yanhong Li¹, Yi Liu² and Yubin Luo³, ¹West China Hospital, Sichuan University, Chengdu, China, ²Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ³Department of Rheumatology & Immunology,, West China Hosptial, Sichuan University, Chengdu, China
Background/Purpose: Increasing studies indicate that immune deregulation occurs prior to symptom in Rheumatoid arthritis (RA). Hematopoietic stem cell (HSC) gives rise to multipotent progenitors differentiating…
Abstract Number: 1122 • 2018 ACR/ARHP Annual Meeting
Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
Ankoor Shah¹, Jan Storek², Rob Woolson³, Lynette Keyes-Elstein⁴, Paul Wallace⁵, Maureen D. Mayes⁶, Leslie Crofford⁷, Daniel E. Furst⁸, Ellen Goldmuntz⁹, Richard Nash¹⁰, Peter McSweeney¹⁰ and Keith Sullivan¹¹, ¹Medicine, Duke University Medical Center, Durham, NC, ²University of Calgary, Calgary, AB, Canada, ³Rho Inc, Chapel Hill, NC, ⁴Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ⁵Roswell Park Cancer Institute, Buffalo, NY, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁸Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁹NIH, Bethesda, MD, ¹⁰Colorado Blood Cancer Institute, Denver, CO, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma:Cyclophosphamide or Transplantation Trial (SCOT) study compared stem cell transplant to monthly cyclophosphamide (CYC) in patients with scleroderma (SSc). We studied baseline lymphocyte…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting
Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Jennifer Franks¹, Viktor Martyanov², Tammara A. Wood², Leslie Crofford³, Lynette Keyes-Elstein⁴, Daniel E. Furst⁵, Ellen Goldmuntz⁶, Maureen D. Mayes⁷, Peter McSweeney⁸, Richard Nash⁸, Keith Sullivan⁹ and Michael L. Whitfield¹⁰, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴Rho, Inc, Chapel Hill, NC, ⁵University of California Los Angeles, Los Angeles, CA, ⁶NIAID, NIH, Bethesda, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸Colorado Blood Cancer Institute, Denver, CO, ⁹Duke University Medical Center, Durham, NC, ¹⁰Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…
Abstract Number: 4 • 2017 Pediatric Rheumatology Symposium
Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome
Lehn K. Weaver¹, Chhanda Biswas¹, Niansheng Chu¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Targeting host-microbiota interactions to limit production of pathogenic myeloid cells that fuel chronic inflammatory responses is of therapeutic interest. Recent evidence suggests that this may…
Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Keith Sullivan¹, Lynette Keyes-Elstein², Peter McSweeney³, Ashley Pinckney², Beverly Welch⁴, Maureen D Mayes⁵, Richard Nash³, Leslie J. Crofford⁶, Sharon Castina², Linda Griffith⁷, Ellen Goldmuntz⁸ and Daniel E. Furst⁹, ¹Duke University, Durham, NC, ²Rho, Inc, Chapel Hill, NC, ³Colorado Blood Cancer Institute, Denver, CO, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine, Vanderbilt University Medical Center, Nasville, TN, ⁷NIAID, NIH, Bethesda, MD, ⁸NIAID, National Institutes of Health, Bethesda, MD, ⁹David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…
Abstract Number: 1369 • 2015 ACR/ARHP Annual Meeting
Enhanced Myelopoiesis Downstream of Toll-like Receptor 9 Activation Drives a Feed-Forward Inflammatory Response
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Monocytes are myeloid cells important for the initiation of inflammation and have been implicated in the pathogenesis of autoimmunity. Monocytes interact with their environment…
Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting
Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
Abstract Number: 1610 • 2013 ACR/ARHP Annual Meeting
Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients
Sarfaraz A. Hasni¹, Gabor G. Illei², Nikolay P. Nikolov³, Francis Hakim⁴, Susan Leitman⁴, James E. Balow⁵, Howard A. Austin⁶, Juan Gea-Banacloche⁴, Unsong Oh⁷, Paulo Muraro⁸, Claude Sportes⁹, Peter E. Lipsky¹⁰, Ronald Gress⁹, Steve Pavletic⁹ and Amrie Grammer¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ³NIDCR, NIH, Bethesda, MD, ⁴NCI, NIH, Bethesda, MD, ⁵Clinical Director, NIDDK, National Institutes of Health, Bethesda, MD, ⁶Kidney Disease Section, NIDDK/NIH, Bethesda, MD, ⁷NINDS, NIH, Bethesda, MD, ⁸NINDS/NIH, Bethesda, MD, ⁹NCI/NIH, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD, ¹¹AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Over the past two decades, approximately 200 patients with severe systemic lupus erythematosus(SLE) have received autologous hematopoietic stem cell transplants (autoHSCT). More than half…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].